NVST Envista Holdings Corporation Common stock, $0.01 par value per share
XNYS
25.84
+0.00%
Pre-market
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
NVST
$25.84
▲ +0.00%
What changed
Recent filings, trades and movesKey stats
$25.84
Pre-market
$25.84
+0.00%
- 52-Week Range
- $18.77 – $30.42
- YTD
- +19.13%
- IV Rank (30D)
- 42.51
- Straddle Price
- $3.58
- P/C Vol Ratio
- 28.46
- Market Cap
- $4.2B
- Open
- $25.75
- Day Range
- $25.29 – $26.10
- Volume
- 2,192,060
- Prev Close
- $25.97
Fair Value
MODEL: LONG
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 4.84% |
| Beta vs SPY | 0.96 |
| Cost of Equity (CAPM) | 9.64% (VRP-adj) |
| WACC | 8.58% |
| Volatility Risk Premium | +17.5pp (IV − HV30) |
| Effective Tax Rate | 21.0% |
| Rev. Growth (YoY, DCF input) | +9.0% |
| DCF Horizon | 10 years explicit + fade |
| Forward Tilt (NTM/TTM) | ×1.09 (applied to P/E, EV/EBITDA, P/S) |
| Free Cash Flow (TTM) | $0.2B |
| Return on Equity (TTM) | 20.5% |
| Book / Price | 72.2% — banking bias active (P/B is primary) |
| Gross Margin (TTM) | 55.2% |
| FCF Margin (TTM) | 8.5% |
| Debt / Equity | 0.47 |
| Quality Score | 3/6 — normal (10y DCF) |
| Market-Implied Growth | +4.4% (reverse-DCF on current price) |
| SMA 50 | $24.36 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $24.01 |
| Bollinger Width / SMA20 | 19.3% (drives anchor stability) |
| Net Debt | $0.3B |
| Market Cap | $4B |
Peers used for multiples: ABT, BDX, GEHC, MDT, ZBH
(filtered from 8 ETF-co-members; sector bias active)
60-Day Conviction
70%
20-Day Fair Value
≈ by Dec 9, 2026
$25.64
α +0.5%
rank 58%
conviction
42%
40-Day Fair Value
≈ by Jan 7, 2027
$26.06
α +2.2%
rank 63%
conviction
67%
60-Day Fair Value
≈ by Feb 5, 2027
$26.25
α +2.9%
rank 71%
conviction
70%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | $34.84 | 30% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | $16.47 | 13% | median 26.0× · 5 peers |
| Peer EV/EBITDA | $32.61 | 13% | median 13.4× · 5 peers |
| Peer P/B | $48.55 | 3% | median 2.6× · 5 peers |
| Peer P/S | $52.58 | 9% | median 2.8× · 5 peers |
| Market Anchor (SMA50) | $24.36 | 32% | stability 54% (BB-width) |
| Options Expected (B-L 30d) | $24.15 | 0% | 6 strikes · skew -1.14 |
As of 2026-11-10 · updated
Related
About
- Industry (SIC)
- DENTAL EQUIPMENT & SUPPLIES (3843) · industry map
- Exchange
- XNYS
- Market Cap
- $4.2B
- Employees
- 12,000
- List Date
- 2019-09-18
- CIK
- 0001757073
- Last Earnings
- Nov 4 after close · −8.2% vs ±12.3% expected
- Next Earnings
- ~Feb 4, 2027 (estimated)
- Headquarters
- Brea, CA
- Homepage
- https://www.envistaco.com
Envista Holdings Corp is a dental products company. It develops, manufactures, and markets portfolios of dental consumables, equipment, and services to dental professionals. The company's business consists of two segments; Specialty Products & Technologies and Equipment & Consumables. The company's Specialty Products & Technologies segment, which derives key revenue, develops, manufactures, and markets dental implant systems, including regenerative solutions, dental prosthetics, and associated treatment software and technologies, as well as orthodontic bracket systems, aligners, and lab produc…
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | 7.86% | -4.21% | 14.81% | -2.49% | 7.38% | 8.21% | 5.26% |
| Feb | 7.00% | 10.60% | -2.67% | -13.02% | -0.20% | 25.58% | 4.55% |
| Mar | 3.37% | 2.27% | 5.88% | 2.20% | -9.25% | -13.82% | -1.56% |
| Apr | 6.00% | -17.63% | -3.15% | -5.43% | -5.96% | 0.15% | -4.34% |
| May | 0.44% | 8.91% | -16.97% | -1.97% | 11.81% | -10.56% | -1.39% |
| Jun | 0.68% | -8.26% | 4.96% | -11.54% | 7.96% | 12.75% | 1.09% |
| Jul | -1.58% | 3.86% | 1.56% | 5.96% | -5.64% | 0.24% | 0.73% |
| Aug | -2.37% | -9.69% | -5.85% | 7.86% | 1.68% | -0.84% | -1.53% |
| Sep | -2.34% | -9.81% | -13.90% | 10.89% | -1.69% | -11.90% | -4.79% |
| Oct | -8.60% | -1.26% | -15.60% | 8.43% | -0.05% | 1.51% | -2.60% |
| Nov | -3.29% | -0.15% | -1.30% | 6.45% | 4.03% | 3.16%* | 1.48% |
| Dec | 18.11% | -4.35% | 0.67% | -13.54% | 4.53% | -- | 1.08% |
| Total | 25.28% | -28.86% | -31.05% | -10.09% | 13.18% | 8.46% | -3.85% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $24.17
SMA 50: $24.34
SMA 200: $25.78
Current: $25.84
EMA 12: $24.98
EMA 26: $24.49
MACD: 0.4911 | Signal: 0.2802
BULLISH
ADX (14): 23.13
WEAK TREND
+DI: 28.94
−DI: 14.97
Momentum Oscillators
RSI (14): 58.30
NEUTRAL
Stoch %K: 62.90
Stoch %D: 62.36
Williams %R: -34.19
Volume & Volatility
BB Upper: $26.53
BB Lower: $21.82
NEUTRAL
OBV: 27,457,980
Vol SMA 20: 3,596,094
Vol ROC: 6.45%
ATR: $1.04
True Range: $0.81
HV 20: 57.8%
HV 30: 48.2%
HV 60: 40.0%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-11-12T00:00:00 – 2026-11-10T00:00:00
AI Analysis
Written before NVST’s Nov 4 earnings report, so it doesn’t reflect the results.
LLM Stock Analysis Report
Executive Summary
Overall Assessment: NEUTRAL (Confidence Level: 6/10)
Key Drivers and Primary Risks:
- Recent positive news headlines on dental imaging, fillings, and clear aligners drove the stock price higher.
- High volatility, as reflected in the beta of 1.27, indicates a higher risk profile compared to the market.
- The options market is pricing in a moderate move by expiration, which may be influenced by upcoming earnings.
2-3 Sentence Investment Thesis:
NVST's recent price action can be attributed to positive news on dental industry trends. However, with high volatility and no clear catalysts driving the stock higher, investors should exercise caution. A short-term pullback could provide an opportunity for long-term investors to establish a position at a more attractive valuation.
Recent News Sentiment Impact:
The recent news headlines have been overwhelmingly positive, contributing to the stock's upward momentum. The majority of articles highlight growth opportunities in the dental industry, which has positively impacted NVST's valuation multiple.
Technical Analysis
Trend Direction:
- Short-term (1-4 weeks): Bullish
- Medium-term (1-3 months): Neutral
- Long-term (3-12 months): Bullish
Support/Resistance Levels:
- Key price levels to monitor:
- Resistance: $28.62 (upper Bollinger Band)
- Support: $26.58 (lower Bollinger Band)
Momentum Signals:
- RSI interpretation: Neutral (49.28)
- MACD signal: Bullish
- Bollinger Bands position: Squeeze
News & Sentiment Analysis
Recent Headlines Summary: The recent news headlines have been positive, highlighting growth opportunities in the dental industry.
Sentiment Assessment: Positive (Aggregate sentiment of recent news articles)
Catalyst Identification: Upcoming earnings and product launches could provide further catalysts for the stock's price movement.
Market Narrative: The positive news on dental trends has aligned with NVST's technical momentum, driving the stock higher.
Risk & Volatility Assessment
Beta Interpretation: High risk relative to the market (beta = 1.27)
Volatility Regime: Current volatility is high compared to historical levels.
Options Market Signals:
- IV rank: Low
- Put/call ratios: Bullish sentiment
- Unusual activity: None notable
Downside Protection: Support levels at $26.58 and risk management considerations should be implemented for investors looking to mitigate potential losses.
Market Context & Positioning
Sector Performance: NVST is outperforming the broader market, with a relative strength of 1.23 (vs XLY).
Institutional Activity: Institutional volume patterns suggest continued interest in NVST, as seen by the increasing on-balance volume and moderate buying pressure.
Correlation Analysis: NVST's price movement has been positively correlated to the overall market (R-squared = 0.43), indicating a high degree of sensitivity to broader market trends.
Relative Valuation: NVST is trading at a premium valuation relative to its peers, with a forward P/E ratio of 35.62 (vs 27.23 for XLY).
Key Levels & Action Items
Critical Price Levels:
- Resistance: $28.62
- Support: $26.58
Breakout/Breakdown Levels:
- Breakout level: $29.15 (2% above current price)
- Breakdown level: $25.20 (2% below current price)
Time-Sensitive Catalysts: Upcoming earnings and product launches could provide further catalysts for the stock's price movement.
Risk Management: Implement a stop-loss order at $26.58 to mitigate potential losses, with an exit strategy in place should the stock break below this level.
I hope this meets your requirements!
Generated
News
All NVST news →
Core sales held up, but China destocking and procurement pressure loom ahead.
Showing 1–10 of 12
Page 1 of 2
Earnings History
22 of 24 under expected move
Avg Expected Move
10.45%
Avg Actual Move
5.58%
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2021-02-10 | After-Close | 8.60% | 2.16% | 0.25x | Within |
| 2021-05-05 | After-Close | 8.03% | 4.67% | 0.58x | Within |
| 2021-08-03 | After-Close | 5.85% | 7.40% | 1.26x | Exceeded |
| 2021-11-03 | After-Close | 8.94% | 5.32% | 0.60x | Within |
| 2022-02-09 | After-Close | 7.38% | 7.04% | 0.95x | Within |
| 2022-05-04 | After-Close | 10.46% | 5.15% | 0.49x | Within |
| 2022-08-03 | After-Close | 7.45% | 3.21% | 0.43x | Within |
| 2022-11-03 | After-Close | 8.39% | 3.06% | 0.36x | Within |
| 2023-02-08 | After-Close | 4.30% | 1.06% | 0.25x | Within |
| 2023-05-03 | After-Close | 6.93% | 6.85% | 0.99x | Within |
| 2023-08-02 | After-Close | 8.34% | 1.03% | 0.12x | Within |
| 2023-11-01 | After-Close | 12.18% | 7.57% | 0.62x | Within |
| 2024-02-07 | After-Close | 9.20% | 7.43% | 0.81x | Within |
| 2024-05-01 | After-Close | 9.87% | 0.30% | 0.03x | Within |
| 2024-08-07 | Pre-Market | 15.39% | 2.92% | 0.19x | Within |
| 2024-10-30 | After-Close | 19.24% | 9.05% | 0.47x | Within |
| 2025-02-05 | After-Close | 14.22% | 5.93% | 0.42x | Within |
| 2025-05-01 | After-Close | 11.47% | 3.98% | 0.35x | Within |
| 2025-07-31 | After-Close | 12.18% | 10.27% | 0.84x | Within |
| 2025-10-29 | After-Close | 10.51% | 0.80% | 0.08x | Within |
| 2026-02-05 | After-Close | 11.03% | 17.77% | 1.61x | Exceeded |
| 2026-05-06 | After-Close | 15.98% | 10.27% | 0.64x | Within |
| 2026-08-05 | Pre-Market | 12.43% | 2.40% | 0.19x | Within |
| 2026-11-04 | After-Close | 12.32% | 8.20% | 0.67x | Within |
Earnings calendar: this week’s reports with expected vs actual moves →
NVST Options Activity & IV Rank
NVST IV rank history, 52-week IV rank and IV percentile →
Volatility Metrics
Current IV: 53.0%
7-DTE IV: 53.9%
Expected Move: $3.58
7-DTE Move: $2.75
Days to Exp: 38 (2026-12-18)
Options Flow · All expiries
Call Volume: 159
Put Volume: 4,526
P/C Volume: 28.465
BEARISH
Call OI: 9,033
Put OI: 8,591
P/C OI: 0.951
Total OI: 17,624
ATM Options Pricing
ATM Call: $1.80
ATM Put: $1.77
Call %: 7.0%
Put %: 6.9%
Chain Summary
Chain Volume: 4,685
Chain OI: 17,624
Last Updated: 11/10/2026
Spread Scanner
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Calendars: the long leg is valued at the short leg’s expiration (Black-Scholes at its current IV) across the range of prices the short leg’s IV implies, giving the best-case profit (R/R = that over the debit) and P(profit).
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Scanning bull put, bear call, iron condor and calendar spreads…
Dealer Positioning
LOW γ vs HISTORY
Estimated net dealer gamma is at the 1st percentile of this name's own daily history, near the low end of its range. This describes current positioning; it is not a forecast or a trading signal.
Gamma percentile
1%
vs own history
GEX tilt
-0.92
OI-weighted, today
Vanna tilt
+0.88
δ-sensitivity to IV
Charm tilt
-0.92
δ-decay vs time
Vanna tilt +0.88: the estimated dealer exposure leans positive, so the modeled hedge would shift noticeably if implied volatility changed.
Charm tilt -0.92: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably as time passes and options approach expiry.
? What is this?
· 4 ATM contracts, 2k total OI
Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.
Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.
Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.
This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
as of Nov 10 · No data
30 DTE / 10d
—
—
pts
EXTREME
as of Nov 10 · No data
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Loading the implied volatility surface…
Volatility Smile
Loading the implied volatility smile…
IV Rank (7 DTE)17.5LowNov 10
IV Rank (30 DTE)42.5MediumNov 10
Straddle Price (30 DTE)$3.58Nov 10
Beta Analysis
Risk Metrics
Beta: 1.2959
Alpha: 18.81%
Correlation: 0.4381
R-Squared: 19.2%
Stock Volatility: 40.5%
Market Volatility: 13.7%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
High volatility - stock moves more than market
High volatility - stock moves more than market
Beta & Alpha Over Time
Notable investors who own NVST
7 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Point72 Hedge fund Steve Cohen | $58.4M | #285 of 1945 | +9.1% | 13F | |
| Renaissance Technologies Hedge fund Jim Simons | $40.1M | #412 of 3138 | +25.9% | 13F | |
| Millennium Management Hedge fund Izzy Englander | $30.2M | #882 of 3716 | new | 13F | |
| Oaktree Capital Asset manager Howard Marks | $10.3M | #72 of 130 | -36.1% | 13F | |
| Citadel Hedge fund Ken Griffin | $1.5M | #3232 of 6285 | -98.8% | 13F | |
| Bridgewater Associates Hedge fund Ray Dalio | $1.1M | #823 of 997 | -45.5% | 13F | |
| Rockefeller Capital Management Family office Rockefeller family | $29K | #3610 of 4729 | -91.8% | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
NVST Institutional Ownership (13F)
Filings for 2026-06-30 · 172 already for 2026-09-30
? 13F Guide
Diluted shares outstanding: 166,450,000 (as of 2026-07-03)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
6 filers$6.68M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Jane Street Group, LLC Custodian | $3.90M | 58.44% | 2026-06-30 |
| 2 | Citadel Advisors LLC Custodian | $2.01M | 30.03% | 2026-06-30 |
| 3 | Susquehanna International Group, LLP Custodian | $292.49K | 4.38% | 2026-06-30 |
| 4 | IMC-Chicago, LLC Custodian | $262.86K | 3.94% | 2026-09-30 |
| 5 | GROUP ONE TRADING LLC Custodian | $115.94K | 1.74% | 2026-06-30 |
| 6 | Simplex Trading, LLC Custodian | $98.57K | 1.48% | 2026-09-30 |
2 filers$3.96M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Jane Street Group, LLC Custodian | $3.96M | 99.94% | 2026-06-30 |
| 2 | Simplex Trading, LLC Custodian | $2.35K | 0.06% | 2026-09-30 |
NVST Insider Trading (Form 4)
Latest: 2026-11-02Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-11-02 | Paul A Keel | Chairman and CEO | Tax (F) | −54,197 | $23.51 | -$1.27M | EDGAR |
| 2026-08-27 | Stefan Nilsson | President, Nobel Biocare | Tax (F) | −804 | $27.47 | -$22.1K | EDGAR |
| 2026-08-27 | Eric D. Hammes | Chief Financial Officer | Tax (F) | −10,885 | $27.47 | -$299.0K | EDGAR |
| 2026-08-27 | Robert Befidi | President, Diagnostics | Tax (F) | −5,147 | $27.47 | -$141.4K | EDGAR |
| 2026-08-27 | Veronica Acurio | President, Orthodontics | Tax (F) | −7,710 | $27.47 | -$211.8K | EDGAR |
| 2026-08-24 | Mischa Reis | SVP, Strategy & Bus. Dev. | Sell (S) | −8,000 | $27.50 | -$220.0K | EDGAR |
| 2026-08-20 | Eric D. Hammes | Chief Financial Officer | Grant (A) | +47,970 RSU | — | EDGAR | |
| 2026-08-20 | Paul A Keel | Chief Executive Officer | Award (A) | +179,730 | — | EDGAR | |
| 2026-05-27 | Paul A Keel | Chief Executive Officer | Tax (F) | −12,811 | $23.43 | -$300.2K | EDGAR |
| 2026-05-21 | R Scott Huennekens | Director | Award (A) | +12,585 | — | EDGAR | |
| 2026-05-21 | Daniel Raskas | Director | Award (A) | +9,330 | — | EDGAR | |
| 2026-05-21 | James Andrew Pierce | Director | Award (A) | +9,330 | — | EDGAR | |
| 2026-05-21 | Kieran Gallahue | Director | Award (A) | +9,330 | — | EDGAR | |
| 2026-05-21 | Vivek Jain | Director | Award (A) | +9,330 | — | EDGAR | |
| 2026-05-21 | Christine A Tsingos | Director | Award (A) | +9,330 | — | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
NVST Insider Holdings
16 insiders · @ $25.84
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Paul A Keel | Chairman and CEO | 497,107 | $12.85M | $506.1K | 12 | 2026-11-02 |
| 2 | Eric D. Hammes | Chief Financial Officer | 99,913 | $2.58M | $400.6K | 8 | 2026-08-27 |
| 3 | R Scott Huennekens | Director | 82,105 | $2.12M | $0 | 7 | 2026-05-21 |
| 4 | Barbara B. Hulit | Director | 79,820 | $2.06M | $0 | 7 | 2025-06-12 |
| 5 | Mark E Nance | General Counsel | 68,577 | $1.77M | -$779.4K | 24 | 2026-02-27 |
| 6 | Stefan Nilsson | President, Nobel Biocare | 61,560 | $1.59M | $0 | 4 | 2026-08-27 |
| 7 | Wendy Carruthers | Director | 59,940 | $1.55M | $0 | 7 | 2026-05-21 |
| 8 | Christine A Tsingos | Director | 59,930 | $1.55M | $0 | 7 | 2026-05-21 |
| 9 | Faez C Kaabi | Chief Accounting Officer | 58,552 | $1.51M | $0 | 6 | 2026-02-27 |
| 10 | Daniel Raskas | Director | 54,010 | $1.40M | $0 | 8 | 2026-05-21 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
NVST Board & Officers
As of SEC filings through Nov 2, 2026Directors 8
- Daniel Raskas · since Sep 17, 2019
- Christine A Tsingos · since Sep 18, 2019
- R Scott Huennekens · since Sep 20, 2019
- Wendy Carruthers · since Sep 20, 2019
- Kieran Gallahue · since Dec 18, 2019
- Vivek Jain · since Apr 7, 2020
- Paul A Keel · since May 1, 2024
- James Andrew Pierce · since Jul 14, 2025
Officers 8
- Paul A Keel · Chief Executive Officer · since May 1, 2024
- Robert Befidi · President, Diagnostics · since Feb 12, 2024
- Stefan Nilsson · President, Nobel Biocare · since Nov 18, 2024
- Veronica Acurio · President, Orthodontics · since Nov 18, 2024
- Eric D. Hammes · Chief Financial Officer · since Aug 8, 2024
- Mark E Nance · General Counsel · listed since Feb 2021
- Mischa Reis · SVP, Strategy & Bus. Dev. · listed since Feb 2021
- Coree K. Thomas · CAO · since Aug 6, 2026
Changes in the last 10 years (50)
| Aug 6, 2026 | Coree K. Thomas became CAO |
| May 28, 2026 | The company announced the departure of Faez C Kaabi as Chief Accounting Officer in an SEC filing |
| Sep 15, 2025 | The company announced the departure of Barbara B. Hulit from the board in an SEC filing |
| Jul 14, 2025 | James Andrew Pierce became a director |
| Nov 18, 2024 | Veronica Acurio became President, Orthodontics |
| Nov 18, 2024 | Stefan Nilsson became President, Nobel Biocare |
| Aug 8, 2024 | Eric D. Hammes became Chief Financial Officer |
| May 1, 2024 | Paul A Keel became a director |
| May 1, 2024 | Paul A Keel became Chief Executive Officer |
| Apr 15, 2024 | The company announced the departure of Amir Aghdaei from the board in an SEC filing |
| Feb 22, 2024 | The company announced the departure of Amir Aghdaei as Chief Executive Officer in an SEC filing |
| Feb 12, 2024 | Robert Befidi became President, Diagnostics |
| Dec 11, 2023 | The company announced the departure of Patrik Eriksson as Senior Vice President in an SEC filing |
| Sep 22, 2023 | Stephen Keller became Principal Financial Officer |
| Sep 22, 2023 | Faez C Kaabi became Chief Accounting Officer |
| Jul 20, 2023 | The company announced the departure of Howard H Yu as Chief Financial Officer in an SEC filing |
| Apr 11, 2023 | The company announced the departure of Jean-Claude Kyrillos as Senior Vice President in an SEC filing |
| Feb 13, 2023 | Eric Conley became SVP, Orthodontics |
| Dec 1, 2021 | Barbara B. Hulit became a director |
| Nov 6, 2021 | The company announced the departure of Teresa Gayle Sheppard from the board in an SEC filing |
| Feb 17, 2021 | Mischa Reis listed as SVP, Strategy & Bus. Dev. (previously Senior Vice President) in SEC filings |
| Feb 17, 2021 | Mark E Nance listed as General Counsel (previously Senior Vice President, GC, Sec) in SEC filings |
| Feb 17, 2021 | Curt W Bludworth listed as Chief Human Resources Officer (previously Senior Vice President, CHRO) in SEC filings |
| Nov 30, 2020 | Kari Lyn Moore listed as VP & Chief Acct. Officer (previously Vice President, CAO) in SEC filings |
| Nov 16, 2020 | Howard H Yu listed as Chief Financial Officer (previously Senior Vice President, CFO) in SEC filings |
| Nov 16, 2020 | Amir Aghdaei listed as Chief Executive Officer (previously President and CEO) in SEC filings |
| Jul 30, 2020 | Teresa Gayle Sheppard became a director |
| Apr 7, 2020 | Vivek Jain became a director |
| Feb 19, 2020 | Jean-Claude Kyrillos became Senior Vice President |
| Dec 18, 2019 | Kieran Gallahue became a director |
| Dec 18, 2019 | Danaher Corp /de/ reported in an SEC filing no longer being a 10% owner |
| Sep 20, 2019 | Wendy Carruthers became a director |
| Sep 20, 2019 | R Scott Huennekens became a director |
| Sep 20, 2019 | Patrik Eriksson became Senior Vice President |
| Sep 20, 2019 | Mischa Reis became Senior Vice President |
| Sep 20, 2019 | Mark E Nance became Senior Vice President, GC, Sec |
| Sep 20, 2019 | Kari Lyn Moore became Vice President, CAO |
| Sep 20, 2019 | Jonathan O Clark became a director |
| Sep 20, 2019 | Jeffrey Kappler became Senior Vice President |
| Sep 20, 2019 | Hans Geiselhoeringer became Senior Vice President |
| Sep 20, 2019 | Dan Houghton became a director |
| Sep 20, 2019 | Curt W Bludworth became Senior Vice President, CHRO |
| Sep 20, 2019 | Allison F. Blackwell became a director |
| Sep 18, 2019 | Christine A Tsingos became a director |
| Sep 17, 2019 | William K Daniel became a director |
| Sep 17, 2019 | Howard H Yu became Senior Vice President, CFO |
| Sep 17, 2019 | Daniel Raskas became a director |
| Sep 17, 2019 | Danaher Corp /de/ became a 10% owner |
| Sep 17, 2019 | Amir Aghdaei became a director |
| Sep 17, 2019 | Amir Aghdaei became President and CEO |
Not reported recently (10)
- Stephen Keller · Last reported as Principal Financial Officer in an SEC filing dated Jun 27, 2024
- Eric Conley · Last reported as SVP, Orthodontics in an SEC filing dated May 29, 2024
- Curt W Bludworth · Last reported as Chief Human Resources Officer in an SEC filing dated Mar 2, 2022
- Kari Lyn Moore · Last reported as VP & Chief Acct. Officer in an SEC filing dated Mar 1, 2022
- Jeffrey Kappler · Last reported as Senior Vice President in an SEC filing dated Nov 19, 2021
- Hans Geiselhoeringer · Last reported as Senior Vice President in an SEC filing dated Feb 26, 2020
- William K Daniel · Last reported as a director in an SEC filing dated Dec 20, 2019
- Allison F. Blackwell · Last reported as a director in an SEC filing dated Sep 20, 2019
- Dan Houghton · Last reported as a director in an SEC filing dated Sep 20, 2019
- Jonathan O Clark · Last reported as a director in an SEC filing dated Sep 20, 2019
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
NVST Proposed Insider Sales (Form 144)
Latest: 2026-08-20
? Form 144 Guide
Last 30d:
0 filings
· Last 90d:
1 filing
· $220K notice value
· 1 unique filer
· 100% under 10b5-1 plans
What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.
Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.
Top 90-day filers:
Reis Mischa (1, $220K)
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2026-08-20 | Reis Mischa | Officer | 8,000 | $220.0K | 2026-08-20 | Fidelity Brokerage Services LLC | 10b5-1 | EDGAR |
| 2026-02-10 | Reis Mischa | Officer | 9,675 | $290.2K | 2026-02-10 | Fidelity Brokerage Services LLC | 10b5-1 | EDGAR |
| 2025-08-25 | Reis Mischa | Officer | 15,000 | $324.0K | 2025-08-25 | Fidelity Brokerage Services LLC | 10b5-1 | EDGAR |
| 2024-08-06 | Conley Eric | Former Officer | 12,798 | $204.8K | 2024-08-06 | Fidelity Brokerage Services LLC | — | EDGAR |
| 2024-06-21 | Conley Eric | Former Officer | 9,185 | $158.6K | 2024-06-21 | Fidelity Brokerage Services LLC | — | EDGAR |
| 2023-10-05 | Yu Howard H | Former Officer | 3,717 | $104.1K | 2023-10-05 | Fidelity Brokerage Services LLC | — | EDGAR |
| 2023-10-04 | Yu Howard H | Former Officer | 60,531 | $1.63M | 2023-10-04 | Fidelity Brokerage Services LLC | — | EDGAR |
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
Recent SEC Filings
Latest: 2026-11-04
Current reports — material events the company must disclose within 4 business days (earnings releases, M&A, executive changes, etc.).
| Filing Date | Event | Link |
|---|---|---|
| 2026-11-04 | Earnings results · Regulation FD disclosure | EDGAR |
| 2026-10-27 | Regulation FD disclosure | EDGAR |
| 2026-09-17 | Regulation FD disclosure | EDGAR |
| 2026-08-19 | Director or officer change · Other events | EDGAR |
| 2026-08-05 | Earnings results · Regulation FD disclosure | EDGAR |
| 2026-06-03 | Director or officer change | EDGAR |
| 2026-05-21 | Shareholder vote results | EDGAR |
| 2026-05-06 | Earnings results · Regulation FD disclosure | EDGAR |
| 2026-02-05 | Earnings results · Regulation FD disclosure | EDGAR |
| 2025-10-29 | Regulation FD disclosure | EDGAR |
Annual report — audited financial statements, MD&A, risk factors. Filed 60–90 days after fiscal year-end.
Quarterly report — unaudited financials and MD&A. Filed 40–45 days after each of the first three fiscal quarters.
| Filing Date | Accession | Link |
|---|---|---|
| 2026-11-04 | 0001757073-26-000087 | EDGAR |
| 2026-08-05 | 0001757073-26-000066 | EDGAR |
| 2026-05-06 | 0001757073-26-000042 | EDGAR |
| 2025-10-30 | 0001757073-25-000058 | EDGAR |
| 2025-07-31 | 0001757073-25-000044 | EDGAR |
| 2025-05-01 | 0001757073-25-000028 | EDGAR |
| 2024-10-30 | 0001757073-24-000078 | EDGAR |
| 2024-08-07 | 0001757073-24-000066 | EDGAR |
| 2024-05-01 | 0001757073-24-000039 | EDGAR |
| 2023-11-01 | 0001757073-23-000071 | EDGAR |
ETF Holders
124 ETFs hold NVST
25 shown · $860.06M total exposure · 0.09% AUM-weighted avg weight
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | IJH iShares Core S&P Mid-Cap ETF | iShares (BlackRock) | 0.12% | $146.3M | $125.2B | 2026-11-06 |
| 2 | VTI Vanguard Morningstar Total Stock Market ETF | Vanguard | 0.01% | $117.2M | — | 2026-09-30 |
| 3 | VB Vanguard Morningstar Small-Cap ETF | Vanguard | 0.05% | $84.9M | — | 2026-09-30 |
| 4 | DFSV Dimensional US Small Cap Value ETF | Dimensional | 0.29% | $77.9M | — | 2026-11-06 |
| 5 | VBR Vanguard Morningstar Small-Cap Value ETF | Vanguard | 0.09% | $55.2M | — | 2026-09-30 |
| 6 | DFAT Dimensional US Targeted Value ETF | Dimensional | 0.17% | $53.7M | — | 2026-11-06 |
| 7 | VXF Vanguard Extended Market ETF | Vanguard | 0.05% | $42.4M | — | 2026-09-30 |
| 8 | MDY State Street® SPDR® S&P MIDCAP 400® ETF Trust | SPDR (State Street) | 0.12% | $30.6M | $25.5B | 2026-11-06 |
| 9 | DFAS Dimensional US Small Cap ETF | Dimensional | 0.09% | $29.3M | — | 2026-11-06 |
| 10 | SPMD State Street® SPDR® Portfolio S&P 400™ Mid Cap ETF | SPDR (State Street) | 0.12% | $22.1M | $18.4B | 2026-11-06 |
| 11 | SCHA Schwab U.S. Small-Cap ETF | Nport | 0.09% | $21.0M | — | 2026-08-31 |
| 12 | IJJ iShares S&P Mid-Cap 400 Value ETF | iShares (BlackRock) | 0.24% | $20.6M | $8.8B | 2026-11-06 |
| 13 | FNDA Schwab Fundamental U.S. Small Company ETF | Nport | 0.23% | $20.5M | — | 2026-08-31 |
| 14 | IHI iShares U.S. Medical Devices ETF | iShares (BlackRock) | 0.50% | $20.2M | $4.1B | 2026-11-06 |
| 15 | DFAC Dimensional US Core Equity 2 ETF | Dimensional | 0.02% | $18.4M | — | 2026-11-06 |
| 16 | IWR iShares Russell Mid-Cap ETF | iShares (BlackRock) | 0.03% | $17.4M | $58.7B | 2026-11-06 |
| 17 | DFMC Dimensional US Micro Cap ETF | Dimensional | 0.22% | $16.2M | — | 2026-11-06 |
| 18 | VHT Vanguard Health Care ETF | Vanguard | 0.05% | $11.7M | — | 2026-09-30 |
| 19 | FXH First Trust Health Care AlphaDEX® Fund | First Trust | 0.98% | $11.4M | $1.2B | 2026-11-06 |
| 20 | IWD iShares Russell 1000 Value ETF | iShares (BlackRock) | 0.01% | $8.9M | $84.7B | 2026-11-06 |
| 21 | AVSC Avantis U.S. Small Cap Equity ETF | Avantis | 0.23% | $7.4M | $3.2B | 2026-11-06 |
| 22 | FMDE Fidelity Enhanced Mid Cap Core ETF | Fidelity | 0.08% | $7.1M | $8.6B | 2026-11-06 |
| 23 | DCOR Dimensional US Core Equity 1 ETF | Dimensional | 0.02% | $6.7M | — | 2026-11-06 |
| 24 | MDYV State Street® SPDR® S&P 400™ Mid Cap Value ETF | SPDR (State Street) | 0.24% | $6.6M | $2.8B | 2026-11-06 |
| 25 | IVOO Vanguard S&P Mid-Cap 400 ETF | Vanguard | 0.11% | $6.3M | — | 2026-09-30 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Trailing P/E
—
TTM Diluted EPS
$0.58
TTM Revenue
$2.86B
TTM Net Income
$95.00M
TTM Op. Cash Flow
$302.60M
Quarterly figures (12 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q2 '26 | 2026-07-03 | $730.50M | $53.70M | $0.33 | $119.20M |
| Q1 '26 | 2026-04-03 | $705.50M | $38.70M | $0.23 | $-3.30M |
| Q4 '25 | 2025-12-31 | $750.60M | $32.90M | $0.20 | $108.00M |
| Q3 '25 | 2025-09-26 | $669.90M | $-30.30M | $-0.18 | $78.70M |
| Q2 '25 | 2025-06-27 | $682.10M | $26.40M | $0.16 | $88.70M |
| Q1 '25 | 2025-03-28 | $616.90M | $18.00M | $0.10 | $300.00K |
| Q4 '24 | 2024-12-31 | $652.90M | $1.20M | $0.01 | $132.40M |
| Q3 '24 | 2024-09-27 | $601.00M | $8.20M | $0.05 | $70.70M |
| Q2 '24 | 2024-06-28 | $633.10M | $-1.15B | $-6.69 | $93.10M |
| Q1 '24 | 2024-03-29 | $623.60M | $23.60M | $0.14 | $40.30M |
| Q4 '23 | 2023-12-31 | $645.60M | $-217.40M | $-1.26 | $102.00M |
| Q3 '23 | 2023-09-29 | $631.30M | $21.50M | $0.12 | $95.50M |
Q2 2026 • period ending 2026-07-03 • filed 2026-08-05
Valuation
Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.
Price Multiples
- P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
- P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
- P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
- EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
- EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
- ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
- ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
- Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
- FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
- Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
- Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
- Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
- Multiples expanding while earnings are flat = sentiment-driven rally.
- Multiples compressing while earnings grow = value coming from fundamentals.
P/E
44.55
P/B
1.40
P/S
1.51
EV/EBITDA
11.87
EV/Sales
1.61
ROE
3.1%
ROA
1.7%
Div Yield
0.00%
FCF Yield
7.04%
Debt/Equity
0.47
Current Ratio
—
Market Cap
$4.30B
as of 2026-11-10
NVST vs Peers
Related companies, largest first| Company | Market cap | P/E | Revenue growth | YTD | IV rank |
|---|---|---|---|---|---|
| LLY Eli Lilly & Co. | $1.26T | 46.5 | +45.5% | +32.6% | 27 |
| ABT Abbott Laboratories | $191.4B | 40.9 | +10.0% | −11.1% | 19 |
| ISRG Intuitive Surgical Inc. | $159.7B | 54.4 | +20.5% | −19.9% | 16 |
| MDT Medtronic plc | $131.5B | 25.0 | +9.8% | +5.8% | 59 |
| BDX Becton, Dickinson and Co. | $58.6B | 53.8 | +6.4% | +9.1% | 31 |
| GEHC GE HealthCare Technologies Inc. Common S | $38.0B | 17.6 | +6.9% | +1.0% | 19 |
| DXCM DexCom, Inc. | $30.2B | 31.5 | +13.0% | +20.1% | 33 |
| ZBH Zimmer Biomet Holdings, Inc. | $20.5B | 26.0 | +8.6% | +19.2% | 19 |
| NVST Envista Holdings Corporation Common stoc | $4.2B | 44.6 | +11.9% | +19.1% | 43 |
| Peer median | $95.1B | 36.2 | +9.9% | +7.4% | 23 |
P/E uses the latest reported trailing-12-month diluted EPS; "—" means no positive earnings or no data.
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
9.77M
SI % of Float
6.14%
Days to Cover
4.09
Short Vol Ratio
71.3%
Free Float
159.17M
Float %
99.1%
Short interest 2026-10-15 • Short volume 2026-11-10 • Float 2026-08-14